卒中：回眸2022

doi:10.3969/j.issn.1673-5765.2023.01.001

摘要/Abstract

关键词: 卒中; 脑血管病; 院前转运; 再灌注; 机械取栓; 静脉溶栓; 缺血预适应; 二级预防; 基因组学

熊云云, 霍晓川, 贾白雪, 濮月华, 李光硕, 王利圆, 程丝, 郝曼均, 王拥军. 卒中：回眸2022[J]. 中国卒中杂志, 2023, 18(01): 1-16.

XIONG Yunyun, HUO Xiaochuan, JIA Baixue, PU Yuehua, LI Guangshuo, WANG Liyuan, CHENG Si, HAO Manjun, WANG Yongjun. Highlights in Stroke in 2022[J]. Chinese Journal of Stroke, 2023, 18(01): 1-16.

[1] SAVER J L，GOYAL M，VAN DER LUGT A，et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke：a meta-analysis[J]. JAMA，2016，316（12）：1279-1288.
[2] PÉREZ DE LA OSSA N，ABILLEIRA S，JOVIN T G，et al. Effect of direct transportation to thrombectomy-capable center vs local stroke center on neurological outcomes in patients with suspected large-vessel occlusion stroke in Nonurban Areas：the RACECAT randomized clinical trial[J]. JAMA，2022，327（18）：1782-1794.
[3] HUBERT G J，HUBERT N D，MAEGERLEIN C，et al. Association between use of a flying intervention team vs patient interhospital transfer and time to endovascular thrombectomy among patients with acute ischemic stroke in Nonurban Germany[J]. JAMA，2022，327（18）：1795-1805.
[4] ZACHRISON K S，SCHWAMM L H. Strategic opportunities to improve stroke systems of care[J]. JAMA，2022，327（18）：1765-1767.
[5] LOGALLO N，NOVOTNY V，ASSMUS J，et al. Tenecteplase versus alteplase for management of acute ischaemic stroke（NOR-TEST）：a phase 3，randomised，open-label，blinded endpoint trial[J]. Lancet Neurol，2017，16（10）：781-788.
[6] KVISTAD C E，NÆSS H，HELLEBERG B H，et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway（NOR-TEST 2，part A）：a phase 3，randomised，open-label，blinded endpoint，non-inferiority trial[J]. Lancet Neurol，2022，21（6）：511-519.
[7] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[8] SANDSET E C，TSIVGOULIS G. Tenecteplase for acute ischaemic stroke[J]. Lancet，2022，400（10347）：138-139.
[9] YANG P，ZHANG Y，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[10] ZI W Z，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[11] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.
[12] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.
[13] MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.
[14] FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.
[15] KHATRI P. Intravenous thrombolysis before thrombectomy for acute ischaemic stroke[J]. Lancet，2022，400（10346）：76-78.
[16] GOYAL M，MENON B K，ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[17] ROMÁN L S，MENON B K，BLASCO J，et al. Imaging features and safety and efficacy of endovascular stroke treatment：a meta-analysis of individual patient-level data[J]. Lancet Neurol，2018，17（10）：895-904.
[18] DALKARA T，ARSAVA E M. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis?[J]. J Cereb Blood Flow Metab，2012，32（12）：2091-2099.
[19] RENU A，MILLÁN M，SAN ROMÁN L，et al. Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke：the CHOICE randomized clinical trial[J]. JAMA，2022，327（9）：1-10.
[20] KHATRI P. Intra-arterial thrombolysis to target occlusions in distal arteries and the microcirculation[J]. IAMA，2022，327（9）：821-823.
[21] SARRAJ A，GROTTA J C，PUJARA D K，et al. Triage imaging and outcome measures for large core stroke thrombectomy - a systematic review and meta-analysis[J]. J Neurointerv Surg，2020，12（12）：1172-1179.
[22] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[23] SCHWAMM L H. In stroke，when is a good outcome good enough?[J]. N Engl J Med，2022，386（14）：1359-1361.
[24] MEYER L，BROOCKS G. Endovascular therapy for large acute strokes[J]. N Engl J Med，2022，386（25）：2440.
[25] ZI W J，QIU Z M，WU D P，et al. Assessment of endovascular treatment for acute basilar artery occlusion via a nationwide prospective registry[J]. JAMA Neurol，2020，77（5）：561-573.
[26] TAO C R，QURESHI A I，YIN Y M，et al. Endovascular treatment versus best medical management in acute basilar artery occlusion strokes：results from the ATTENTION multicenter registry[J]. Circulation，2022，146（1）：6-17.
[27] JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.
[28] TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.
[29] SCHONEWILLE W J. Favorable outcomes in endovascular therapy for basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1428-1429.
[30] STEEN W，GRAAF R A，CHALOS V，et al. Safety and efficacy of aspirin，unfractionated heparin，both，or neither during endovascular stroke treatment（MR CLEAN-MED）：an open-label，multicentre，randomised controlled trial[J]. Lancet，2022，399（10329）：1059-1069.
[31] ALMEKHLAFI M A，COUTTS S B. Anti-thrombotics cause harm in the setting of stroke thrombectomy[J]. Lancet，2022，399（10329）：1025-1026.
[32] HEO J H，LEE K Y，KIM S H，et al. Immediate reocclusion following a successful thrombolysis in acute stroke：a pilot study[J]. Neurology，2003，60（10）：1684-1687.
[33] CANNON C P，WEINTRAUB W S，DEMOPOULOS L A，et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban[J]. N Engl J Med，2001，344（25）：1879-1887.
[34] QIU Z M，LI F L，SANG H F，et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke：the RESCUE BT randomized clinical trial[J]. JAMA，2022，328（6）：543-553.
[35] YANG P F，SONG L L，ZHANG Y W，et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke（ENCHANTED2/MT）：a multicentre，open-label，blinded-endpoint，randomised controlled trial[J]. Lancet，2022，400（10363）：1585-1596.
[36] MISTRY E A，NGUYEN T N. Blood pressure goals after mechanical thrombectomy：a moving target[J]. Lancet，2022，400（10363）：1558-1559.
[37] WEIR P，MAGUIRE R，O’SULLIVAN S E，et al. A meta-analysis of remote ischaemic conditioning in experimental stroke[J]. J Cereb Blood Flow Metab，2021，41（1）：3-13.
[38] ENGLAND T J，HEDSTROM A，O’SULLIVAN S，et al. RECAST（remote ischemic conditioning after stroke trial）：a pilot randomized placebo controlled phaseⅡtrial in acute ischemic stroke[J]. Stroke，2017，48（5）：1412-1415.
[39] HOU C B，LAN J，LIN Y N，et al. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis（the RICA trial）：a multicentre，randomised，double-blind sham-controlled trial in China[J]. Lancet Neurol，2022，21（12）：1089-1098.
[40] GANESH A，SMITH E E，HILL M D. Remote ischaemic conditioning for stroke prevention[J]. Lancet Neurol，2022，21（12）：1062-1063.
[41] CHEN H S，CUI Y，LI X Q，et al. Effect of remote ischemic conditioning vs usual care on neurologic function in patients with acute moderate ischemic stroke：the RICAMIS randomized clinical trial[J]. JAMA，2022，328（7）：627-636.
[42] HESS D C，BLAUENFELDT R A，ANDERSEN G. Remote ischemic conditioning：feasible and potentially beneficial for ischemic stroke[J]. JAMA，2022，328（7）：622-624.
[43] DERDEYN C P，CHIMOWITZ M I，LYNN M J，et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis（SAMMPRIS）：the final results of a randomised trial[J]. Lancet，2014，383（9914）：333-341.
[44] GAO P，WANG T，WANG D M，et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis：the CASSISS randomized clinical trial[J]. JAMA，2022，328（6）：534-542.
[45] BODEN W E，O’ROURKE R A，TEO K K，et al. Optimal medical therapy with or without PCI for stable coronary disease[J]. N Engl J Med，2007，356（15）：1503-1516.
[46] SEDLIS S P，HARTIGAN P M，TEO K K，et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease[J]. N Engl J Med，2015，373（20）：1937-1946.
[47] MARON D J，HOCHMAN J S，REYNOLDS H R，et al. Initial invasive or conservative strategy for stable coronary disease[J]. N Engl J Med，2020，382（15）：1395-1407.
[48] CHANG R W，TUCKER L Y，ROTHENBERG K A，et al. Incidence of ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，327（20）：1974-1982.
[49] STERPETTI A V，ARICI V，BOZZANI A. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，328（12）：1255-1256.
[50] HUANG K W，CHEN C W，WEI J C. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，328（12）：1256.
[51] SABATER-LLEAL M，HUANG J，CHASMAN D，et al. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease[J]. Circulation，2013，128（12）：1310-1324.
[52] MALIK R，CHAUHAN G，TRAYLOR M，et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet，2018，50（4）：524-537.
[53] MISHRA A，MALIK R，HACHIYA T，et al. Stroke genetics informs drug discovery and risk prediction across ancestries[J]. Nature，2022，611（7934）：115-123.
[54] GALLEGO-FABREGA C，MUIÑO E，CÁRCEL-MÁRQUEZ J，et al. Genome-wide studies in ischaemic stroke：are genetics only useful for finding genes？[J]. Int J Mol Sci，2022，23（12）：6840.

卒中：回眸2022

Highlights in Stroke in 2022

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	曹黎明, 任力杰. 急性缺血性卒中诊疗技术的进展与展望[J]. 中国卒中杂志, 2024, 19(9): 983-989.
[2]	符鹏程, 曹黎明, 朱佳倩, 赵桂玉, 徐格林. 大动脉粥样硬化性缺血性卒中再灌注治疗的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1004-1011.
[3]	张丽苹, 曹黎明, 肖楠, 廖雨琦, 池枫, 余艳妮, 任力杰. 纳米材料在缺血性卒中诊疗中的研究进展及挑战[J]. 中国卒中杂志, 2024, 19(9): 1012-1017.
[4]	姜河, 王珵, 陈祥华, 许春香. 五种院前卒中筛查量表对院内急性大血管闭塞性缺血性卒中的预测价值[J]. 中国卒中杂志, 2024, 19(9): 1018-1024.
[5]	王晓蕊, 骆嵩, 邹良玉, 屈洪党, 崔雪, 赵玉洁. 嗜酸性粒细胞与单核细胞比值预测急性缺血性卒中患者静脉溶栓预后的价值研究 [J]. 中国卒中杂志, 2024, 19(9): 1025-1033.
[6]	王铄, 余苹, 张宁, 王春雪. 2013—2023年缺血性卒中与睡眠相关性研究的文献计量学分析 [J]. 中国卒中杂志, 2024, 19(9): 1040-1047.
[7]	周宏宇, 李子孝, 王拥军. 基于影像组学预测大脑年龄与缺血性卒中的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1066-1076.
[8]	阿娜古丽·阿不拉尼压孜, 吴晓欣, 李骄星, 李竹浩, 盛文利. 急性缺血性卒中磁敏感血管征影响因素及临床应用的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1077-1085.
[9]	杨金波, 张聪. 高分辨率血管壁成像在缺血性卒中患者中的应用进展[J]. 中国卒中杂志, 2024, 19(9): 1086-1093.
[10]	吴春艳, 尹雅诗, 王广志, 岳奎涛. 急性缺血性卒中不同时间窗影像学评价及应用进展[J]. 中国卒中杂志, 2024, 19(9): 1094-1101.
[11]	王也, 魏宸铭, 李秀丽, 武剑. 多元化教学模式在大学附属教学医院卒中绿色通道培训中的应用[J]. 中国卒中杂志, 2024, 19(9): 1102-1109.
[12]	单凯, 赵梦, 王春娟, 李子孝, 王晓岩. 卒中及共患疾病诊疗模式探索与实践 [J]. 中国卒中杂志, 2024, 19(8): 863-865.
[13]	梁艳超, 王晓岩, 单凯. 基于DMAIC模型的妊娠合并脑血管病急诊就诊流程优化研究 [J]. 中国卒中杂志, 2024, 19(8): 873-879.
[14]	张梦若, 徐守臣, 隋翠翠, 李玉奎, 王雪莉. 下肢康复机器人联合头针治疗对老年缺血性卒中患者步行效率和协调功能影响调查 [J]. 中国卒中杂志, 2024, 19(8): 902-908.
[15]	薛明月, 张慧鑫, 苏丹, 李丽霞, 李晶玮, 李虹. 缺血性卒中患者服药依从性影响因素分析 [J]. 中国卒中杂志, 2024, 19(8): 909-914.